3 insiders reported 7 Form 4 transactions for Outlook Therapeutics, Inc. (OTLK) over the past 18 months (most recent 2026-06-03). Recent activity: Haddadin Yezan Munther (Director) Buy 29,000 shares, Sukhtian Ghiath M. (Director) Buy 8.5M shares, GMS Ventures & Investments (Director) Buy 8.5M shares, Sukhtian Ghiath M. (Director) Buy 4.3M shares, GMS Ventures & Investments (Director) Buy 4.3M shares. Source: SEC Form 4.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-03 | Haddadin Yezan Munther | Director | Buy | 29,000 | $24,145 |
| 2026-06-01 | Sukhtian Ghiath M. | Director | Buy | 8.5M | $5.0M |
| 2026-06-01 | GMS Ventures & Investments | Director | Buy | 8.5M | $5.0M |
| 2025-05-28 | Sukhtian Ghiath M. | Director | Buy | 4.3M | $6.0M |
| 2025-05-28 | GMS Ventures & Investments | Director | Buy | 4.3M | $6.0M |
| 2025-03-12 | GMS Ventures & Investments | Director | Buy | 3.5M | $8.7M |
| 2025-03-12 | Sukhtian Ghiath M. | Director | Buy | 3.5M | $8.7M |
Source: SEC Form 4 filings · as of 2026-06-03